Retrospective Study
Copyright ©The Author(s) 2023.
World J Clin Cases. Aug 6, 2023; 11(22): 5204-5214
Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5204
Table 1 Patients’ baseline characteristics (n = 279)
Age (yr)65.9 ± 12.8 (21-86)
Sex (male/female)118/161
Genotype (1b/2a/2b/1a+2b/3a+3b/unknown)121/54/25/1/2/26
Interferon (yes/no/unknown)64/215/0
HCV RNA (LogIU/mL)5.87 ± 0.91 (2.3-7.3)
ALT (IU/L)71.6 ± 216.6 (4-497)
Total bilirubin (mg/dL)0.86 ± 0.90 (0.05-9.0)
Alb (g/dL)4.15 ± 0.39 (2.70-5.25)
WBC (104/mm3)5.10 ± 1.72 (2.0-12.2)
Hb (g/dL)13.7 ± 1.70 (8.3-18.1)
Plt (104/mm3)17.2 ± 6.30 (4.4-40.4)
PT (%)99.7 ± 18.3 (11.5-154.3)
AFP (ng/mL)8.46 ± 16.27 (0.6-140.5)
Vs (m/s)1.55 ± 0.25 (1.03-2.62)
Fib-4 index3.41 ± 2.89 (0.23-22.0)
aMAP score58.7 ± 8.6 (27.4-76.7)
Observation period (M)33.8 ± 26.2 (6-85)
Hepatocellular carcinoma (Yes/No)12/267